Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01360840 · ClinicalTrials.gov registry record · Phase 2
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01360840 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 180 participants.
The verdict
NCT01360840, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC).
Interventions
- OTHER Placebo
- OTHER Standard of Care (SoC)
- DRUG EMD 525797
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01360840
The ClinicalTrials.gov registry entry for NCT01360840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01360840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01360840 about?
NCT01360840 is a clinical study titled "EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer". The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cance...
What is the current status of trial NCT01360840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2011-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01360840?
The interventions under investigation include: Placebo (OTHER), Standard of Care (SoC) (OTHER), EMD 525797 (DRUG).
Who is sponsoring clinical trial NCT01360840?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.